Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in the areas of ophthalmology, rheumatology, anesthesia, and antidotes in the United States. The company's Ophthalmic Segment markets diagnostic products, including mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, and angiography dyes, which are used in the office setting. It also sells therapeutic products, such as antibiotics, anti-infectives, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers and other national account customers. In addition, this segment offers non-pharmaceutical products, including various artificial tear solutions, preservative-free lubricating ointments, eyelid cleansers, vitamin supplements, and contact lens accessories. The company's Hospital Drugs and Injectables Segment markets specialty injectable pharmaceutical products, including antidotes and anesthesia, as well as products used in the treatment of rheumatoid arthritis and pain management. It markets products to hospitals through wholesalers and other national account customers, as well as directly to medical specialists. The company's Biologics and Vaccines Segment markets adult Tetanus-Diphtheria vaccines directly to hospitals and physicians, as well as through wholesalers and national distributors. Its Contract Services Segment manufactures products for third party pharmaceutical and biotechnology customers. The company also markets and distributes vaccines purchased from outside sources. Its customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, and other pharmaceutical companies.

Warnex Inc., a life sciences company, provides laboratory services to the pharmaceutical and healthcare sectors in Canada, the United States, and internationally. The company’s Analytical Services division provides quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies to pharmaceutical, biotechnology, cosmetics, and veterinary industries. This division offers a range of ICH stability conditions and provides stability management, and revalidates existing methods to ensure compliance with regulatory requirements and performs technology transfers. Its Bioanalytical Services division offers a range of services to the pharmaceutical and biotechnology industries. It specializes in bioavailability and bioequivalence studies, as well as provides services in the areas of research and development, method development, validation, production, and quality assurance.This division helps companies in their drug development programs by carrying out analyses generated in pre-clinical studies and proceeding with evaluation of the drug in human clinical trials. It also provides services to generic drug industry by analyzing physiological fluid samples obtained from studies in humans. The company’s Medical Laboratories division provides specialized laboratory services to the healthcare sector. It offers Prenatest prenatal screening test, which enables pregnant women to find out their risk of carrying a fetus that may be affected by common birth anomalies. This division also provides PRO-DNATM paternity test; genetic testing for human identification, molecular diagnostics, and pharmacogenetics; and testing services in the areas of endocrinology, hematology, infectious diseases, obstetrics/gynecology, and oncology. The company was formerly known as Warnex Pharma, Inc. and changed its name to Warnex Inc. in June 2001. Warnex Inc. was founded in 1996 and is headquartered in Laval, Canada.

Mikart offers contract pharmaceutical manufacturing services, specializing in oral capsule and tablet formulations. Tablets and capsules can be immediate or time-release; the company also makes liquid formulations and provides specialty packaging, including laminated foil, blister, and pouches. Its facilities have the capacity to produce everything from small pilot-scale batches all the way up to full-scale commercial production. Other services include drug development, feasibility studies, and product testing. Mikart will also walk customers through all the required regulatory processes.

CeMines Biologics, LLC company is working on more accurate, simple blood tests to diagnose lung, breast, prostate, and other cancers. The firm's CeMines Molecular FingerPrinting technology uses biostatistics to determine if disease biomarkers found in a patient's blood sample indicate the likelihood of cancer. Its lead product candidate, CeMines CellCorrect LAb, detects patterns of key antibodies that indicate cancer cells are present. Noted researcher Toomas Neuman, whose use of stem cells to treat Parkinson's disease triggered a national debate, founded the company in 2000 with several other officers of the company, which is led by CEO Richard Cavalli.

Avacta will take a closer look and get back with you. The biophysics company makes its money from the exact science of detecting molecules. Its Avacta Analysis arm provides analytical and research services to the pharmaceutical, healthcare, and personal care industries. It also offers expert witness services to assist in pharmaceutical patent disputes and suspected counterfeiting cases. The company's technology arm has developed a product to help drug developers analyze and predict the potential usefulness of biological drug compounds. The company also owns veterinary laboratory services provider YorkTest Veterinary Services, and diagnostic test maker Curidium Medica.

Beijing Tongrentang Co., Ltd. company makes and sells a variety of traditional Chinese herbal medicines under the Tongrentang brand. Products include treatments for a number of maladies including colds and fevers, and preparations designed to improve circulation and kidney function. Tongrentang also exports its herbal remedies and has expanded beyond Chinese borders through a number of joint ventures and subsidiaries, establishing retail drug stores and clinics specializing in traditional Chinese medicine. The company's origins date back more than 300 years as a family business offering its remedies in Beijing during the Qing Dynasty.

Quick-Med Technologies, Inc. was founded in 1997 and is headquartered in Gainesville, Florida. Quick-Med Technologies, Inc., a life sciences company, develops technologies for the medical and consumer healthcare markets in the United States. Quick-Med Technologies's technologies under development include NIMBUS, a family of organic molecules or polymers that are bio-engineered to have antimicrobial, hemostatic, and other properties, which could be used in a range of medical device applications, including contact lenses, wound dressings, incontinence products, or disposable gloves; and Stay Fresh, a chemical formulation for textiles that provides a durable antimicrobial agent, which can be bonded to fibers or fabrics so as to retain the biocidal property through various launderings and is suitable for a range of applications, including apparel, sportswear, active wear, and work wear, as well as furnishings, such as linens, drapes, and towels. Its other technologies under development comprise NimbuDerm, a novel copolymer used as a persistent hand sanitizer; and MultiStat, a family of matrix metalloproteinase inhibitors that are used for the maintenance, healing, and repair of skin and eyes.

GW was founded in 1998. GW Pharmaceuticals has "high" hopes that its products will help relieve the pain and muscle stiffness that have resulted from cancer, multiple sclerosis, and surgery. The company develops prescription medicinal drugs derived from an hybrid form of cannabis that doesn't cause a psychotropic high. GW's lead drug candidate is Sativex, a whole-plant cannabis extract delivered by an oral spray. Sativex has been approved in Canada for the treatment of pain caused by multiple sclerosis. The company has agreed to let Bayer market the drug in the UK and Canada.

AVEO Pharmaceuticals' models don't pout, strut, or even turn heads -- unless you're a cancer drug researcher. The biotech firm develops cancer models to uncover how genes mutate into tumors and how tumors progress through additional mutations. AVEO then builds genetic profiles of such tumors and applies them to antibody (protein) drug candidates in preclinical and clinical development to help predict actual human responses. In addition to its own pipeline of potential drugs, AVEO has partnered with other pharmaceutical developers to apply its Human Response Platform to their drug candidates.

ImaRx Therapeutics, Inc. company was founded in 1999. ImaRx Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the development of therapies for stroke and other vascular disorders, using its microbubble technology. Its lead program, SonoLysis, involves the administration of its MRX-801 microspheres and ultrasound to break up blood clots and restore blood flow to oxygen deprived tissues. The MRX-801 microspheres are a proprietary formulation of a lipid shell encapsulating an inert biocompatible gas. Discontinued operations In September 2008, the company divested its urokinase business to Microbix.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.